Overall, our study linked transcriptional HLA-I APM suppression in melanoma to ICB resistance and nominated RIG-I as a druggable therapeutic target to restore antigen processing and presentation and overcome T cell resistance of IFN-sensitive and IFN-resistant tumor cells. The gene discussed is RIGI; the disease is neoplasm.